Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-02-17 07:00:23
Oslo, Norway, 17 February 2022 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard-to-treat solid
tumors, today announces its fourth quarter 2021 results. Targovax's CEO will
give an online presentation and update on the clinical program to investors,
analysts and the press at 10:00 CET today (details below).
2021 HIGHLIGHTS
ONCOS-102
· Reported class-leading ORR of 35% for ONCOS-102 in PD1-refractory melanoma,
associated with broad and powerful immune activation in responding tumors
· Reported 25.0 months median Overall Survival (mOS) for ONCOS-102 combined
with chemotherapy in first line mesothelioma
· Granted two Fast-Track designations for ONCOS-102 by the US FDA, for both
PD1-refractory melanoma and malignant pleural mesothelioma
NextGen circRNA ONCOS vectors
· Expanded the pipeline programs into circular RNA delivery
· Appointed Dr. Erik Digman Wiklund as CEO, previous Targovax CBO and CFO and
circRNA co-discoverer
· Appointed circRNA co-discoverer Dr. Thomas B Hansen as VP of Research to
lead the NextGen circRNA ONCOS pipeline program
· Announced a research collaboration with Prof. Michael Uhlin at Karolinska
Institutet in Stockholm for development and characterization of NextGen ONCOS
viruses
Mutant KRAS
· Awarded two prestigious research grants towards the TG mut KRAS vaccine
program totaling NOK 18m over four years